Delivered-To: oc.tjphuhs@gmail.com Received: by 2002:a54:2b46:0:b0:2c4:e372:78d6 with SMTP id y6csp1391277ecr; Thu, 26 Mar 2026 08:39:57 -0700 (PDT) X-Received: by 2002:a05:690c:c513:b0:79b:cced:232e with SMTP id 00721157ae682-79bcced2490mr28609757b3.17.1774539597349; Thu, 26 Mar 2026 08:39:57 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1774539597; cv=none; d=google.com; s=arc-20240605; b=WiPHGq/pAmaCSrqocHPXEz/N/bH5kKK50Lrf8ttURS7pBEqTcjWv35SgyPYDsRfeUo 1FUVU0zQXSIwpv33/kOovKUYX+kM+HPWSgFKsV6GXYb8QglINiSxgF1Twupl/W3g8a7g zRWhXNzsD1dAMdRI7cFRMSvRjaOk2GnkFYo4UV7q6aHcEpeCc2Ka/RGNiDc8D+MSa2jr efxKZx/YR9PzSgo6poKWLft2alfSZc+i1E2ePxXw7kwcYj7slb2UrIrdy5YTvg9pjzji T7zgvu2PWxYhCjGvleiVLKphXpIKdRL7Y8z3shCcLj1UEqR+gwlhEYrxVVg6YGVhXMzY aN/w== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=mime-version:subject:references:in-reply-to:message-id:to:from:date :dkim-signature; bh=koBL+C48HhVLHWK0lb4BBXvN0zlZlR4zk5lgB21xUio=; fh=F6Qtq/PC/9aW+A0Z/30DYnuZeFJIQSXKTJRrYsjMofs=; b=VIcZ36Fu/+wlIQrs0xxKOfqK0fog0bq9HGV0Pr9yS1J0sCoKPY5Yr59bFnSImCsOzu QHjyrEAK8sRb25wbhHkJ3FWs/i8rQvaN7/eMa/L/rOyiOvHQX9Zqg7FsPK5OzllqQVTw /excYntQTMmze5IDMd82NmyQqVWuD/G1oFZL+nONTykHwUsi7HP8QGR21dC9GHmmljD/ o8NQnjmBSpr7UI9a7L7DfRCVlx0bYExRqEMu/+9bU1tZY3ODXufNEQdCuFTJnDAJTqDg i13TdmAiDGbfY9IhZzz9YIbx5saVEelHS3ZM2VFf3rFj6XvQ7zRPaVWOSKuCO590U1x5 9bPQ==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@gmail.com header.s=20251104 header.b=QsdMJcLR; spf=pass (google.com: domain of tjphuhs@gmail.com designates 209.85.220.41 as permitted sender) smtp.mailfrom=tjphuhs@gmail.com; dmarc=pass (p=NONE sp=QUARANTINE dis=NONE) header.from=gmail.com; dara=pass header.i=@gmail.com Return-Path: Received: from mail-sor-f41.google.com (mail-sor-f41.google.com. [209.85.220.41]) by mx.google.com with SMTPS id 00721157ae682-79b1e4524e3sor18273947b3.12.2026.03.26.08.39.56 for (Google Transport Security); Thu, 26 Mar 2026 08:39:57 -0700 (PDT) Received-SPF: pass (google.com: domain of tjphuhs@gmail.com designates 209.85.220.41 as permitted sender) client-ip=209.85.220.41; Authentication-Results: mx.google.com; dkim=pass header.i=@gmail.com header.s=20251104 header.b=QsdMJcLR; spf=pass (google.com: domain of tjphuhs@gmail.com designates 209.85.220.41 as permitted sender) smtp.mailfrom=tjphuhs@gmail.com; dmarc=pass (p=NONE sp=QUARANTINE dis=NONE) header.from=gmail.com; dara=pass header.i=@gmail.com DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=gmail.com; s=20251104; t=1774539595; x=1775144395; dara=google.com; h=mime-version:subject:references:in-reply-to:message-id:to:from:date :from:to:cc:subject:date:message-id:reply-to; bh=koBL+C48HhVLHWK0lb4BBXvN0zlZlR4zk5lgB21xUio=; b=QsdMJcLR6ipobnbZqJ1wJpnqUYSZyY4TxkHfSCYA+avgMN7Q5Z0DrGbEENvQ9V8mV0 M0FCi28O82GsgyRbbDGVRJ8XRcnz/plo8gC9XoJjZT74koIgFm0kPxo8YySMiGz4chap ySbADEGjDN86ghIq0opdoBDWmtEUfa1vaRQFSl+cO7EHsEdIlGl8nCh5ArztmjpH4VQ6 k9cHCd6ckYPXNIeDvlmlSu6ycY8AV6XiZCTjPpZYB/IbZkeRW/4nrzNv7SOEiZlKAasO MHXNPlz7bV1Lg/kngDllMCLt9n7NcPky0JT80jRjhlmFnP9LOFbLsXBBknXkOFRNSGU7 xpWw== X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=1e100.net; s=20251104; t=1774539595; x=1775144395; h=mime-version:subject:references:in-reply-to:message-id:to:from:date :x-gm-gg:x-gm-message-state:from:to:cc:subject:date:message-id :reply-to; bh=koBL+C48HhVLHWK0lb4BBXvN0zlZlR4zk5lgB21xUio=; b=G5BfsPTe+PeOL2arPTPRTxCcAenpwDxPb9z0a+Zppgp3tb1/vSNvAZve6B/HIZqMd6 74ZuRnQ5qQ+LJanXjy8hfFFfUgJZqphK66ANHpBtUGSU2D5Ooz0AURZ7nx93Iqyy6wrY 9UIkqXuNvQzAQVkB17n14jlvUBCNgz7HVxZgX8Y7I4a1v5rZ95arMOsFytbpd8L83pyF +iFOfFrfJqsIt+ldjrOhd3VaHG4PE0uyPC4c+iC8PoBZ4iZrn5L8vfHFtuO050x62BsH RM3P4j57azO1c3SahVQNOT62/hfTC5L2U3NqMLYbBx89ArrAU8gveWDhkwyrSvR6D5/G 5qpQ== X-Gm-Message-State: AOJu0YyYJGnRHDv1ip4770XU1qG75ZHBbyPjKuhhuCPQZn65qxNz6pFX Uzb+Q5NNZVZ8g9cyEF6pqPg83l/US226RpYrvXRKirbCz4iIIf5UxZ+VMtKybBFq X-Gm-Gg: ATEYQzzHKJce38lHmhh1HDQtOTkrpk+dLNw5Fcp2l+rQiEKh874gCOsawCkXyKHYQK1 aW6EiWkW7n6VcdpgkSQ/SV9nEvhIGUgKZ/KjdJvP+0ZjPijR5nub7niUt6hSAqS3WHTx3EM2hnv UlT0AIRaoAlTNuxfjUqtCCXEynx4pPn7/dvxKFTG76tgBwyqwfeBVMkglm9IrhMHKUVZmOrWuT6 hH8PTv03h12oqeFTGLK3kSx/GXCnOUO07eHz0xZQYSpoi31JXP8vnNu2pHm3iPBKoTbje2Ep9pS QNqQIGlDVM5zoUj3br2RBwrhIyDiWQYYyEcaCvBQ24MOfkCG+x0K5RlwwNyPu7tL3k0m6COmw2H nhWP91UGWNvL1kS8YHOGCCtVf0EJune8V0cT2rgOBD4EfH5ohSNyYhLJJkL+ld06yIZYHbnpou7 EDDJbGDoXSt01FPSkNU/cHPkZ9wXDrMGfeFlQXbvJJmc3lPVmII0VejQ5UpRA0uYpyzdwzf1WUc b0c X-Received: by 2002:a05:690c:d93:b0:79a:bde3:708f with SMTP id 00721157ae682-79acf6219b8mr83962947b3.16.1774539594967; Thu, 26 Mar 2026 08:39:54 -0700 (PDT) Return-Path: Received: from [2607:fb90:e204:5c1f::f0:ffff] ([2607:fb90:e204:5c1f:1145:fbcb:a4b8:72b]) by smtp.gmail.com with ESMTPSA id 00721157ae682-79b1e4116a2sm14653647b3.41.2026.03.26.08.39.53 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 26 Mar 2026 08:39:54 -0700 (PDT) Date: Thu, 26 Mar 2026 11:39:28 -0400 From: tjphuhs@gmail.com To: "=?utf-8?Q?oc.tjphuhs=40gmail.com?=" Message-ID: <16c56520-88fa-4be6-95ab-4b956c93e037@Spark> In-Reply-To: <20260326143040.3.94c25ea1643e28a2@mg-d0.substack.com> References: <20260326143040.3.94c25ea1643e28a2@mg-d0.substack.com> Subject: Fwd: GW501516 (Cardarine) =?utf-8?Q?=E2=80=94_?=Full Research Breakdown: Mechanisms, Cancer Data, and What the Human Trials Actually Show X-Readdle-Message-ID: 16c56520-88fa-4be6-95ab-4b956c93e037@Spark MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="69c55348_388bd13e_733a" --69c55348_388bd13e_733a Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline ---------- =46orwarded message ---------- =46rom: Derek from Peptide Price Date: Mar 26, 2026 at 10:30=E2=80=AFAM -0400 To: tjphuhs=40gmail.com Subject: GW501516 (Cardarine) =E2=80=94 =46ull Research Breakdown: Mechan= isms, Cancer Data, and What the Human Trials Actually Show > =46or research purposes only. > =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD > =46orwarded this email=3F Subscribe here for more > GW501516 (Cardarine) =E2=80=94 =46ull Research Breakdown: Mechanisms, C= ancer Data, and What the Human Trials Actually Show > Derek > Mar 26 > > READ IN APP > > =46or research purposes only. Not for human consumption. > What Is Cardarine=3F > Cardarine (also known as GW501516 or GW1516) is a synthetic compound th= at activates something called the PPAR=CE=B4 receptor (peroxisome prolife= rator-activated receptor delta). This receptor controls genes involved in= energy metabolism =E2=80=94 specifically how your body burns fat and use= s fuel. > It was originally developed to treat high cholesterol and metabolic dis= orders, and early human clinical trials showed very promising results. Ho= wever, animal studies revealed a serious cancer concern, and all further = pharmaceutical research was abandoned. Despite this, it remains widely us= ed in the fitness community for fat loss and endurance. > It is not a SARM =E2=80=94 it has zero activity at the androgen recepto= r. It is on the WADA prohibited list, which confirms it has measurable pe= rformance effects. (Kintz et al., 2021) > Upgrade to paid > What Does Cardarine Actually Do=3F > Here=E2=80=99s a straightforward breakdown of the evidence-based effect= s: > =46at Loss & Metabolism > > =E2=80=A2 > Stimulates fatty acid beta-oxidation =E2=80=94 your body bu= rns stored fat for fuel more efficiently (Grewal et al., 2016) > =E2=80=A2 > Promotes fat loss in a caloric deficit > =E2=80=A2 > Reduces liver fat content =E2=80=94 one human trial showed = a 20% reduction in just two weeks at 10mg/day (Park et al., 2021) > =E2=80=A2 > Reverses metabolic abnormalities in obese and pre-diabetic = research subjects (Bianchi et al., 2023) > > Blood Work / Lipid Parameters At 10mg/day in human clinical trials, car= darine produced measurable improvements (Bianchi et al., 2023; Park et al= ., 2021): > > =E2=80=A2 > HDL (=E2=80=9Dgood cholesterol=E2=80=9D) increased up to 16= .9% > =E2=80=A2 > LDL reduced 7=E2=80=9323% > =E2=80=A2 > Triglycerides reduced 17=E2=80=9330% > =E2=80=A2 > =46asting insulin reduced =7E11% > =E2=80=A2 > =46ree fatty acids reduced =7E20% > > These improvements showed up in as little as two weeks. > Endurance & Performance > > =E2=80=A2 > Increases stamina and endurance capacity (Narkar et al., 20= 08) > =E2=80=A2 > Shown to increase Type I (slow-twitch, endurance) muscle fi= bers in animal models (Wang et al., 2004) > =E2=80=A2 > Improves how skeletal and cardiac muscle uses energy (Li et= al., 2015) > > Other Notable Effects > > =E2=80=A2 > Improves insulin sensitivity (Grewal et al., 2016) > =E2=80=A2 > Anti-inflammatory effects (systemic, brain, lungs, kidneys,= liver) (Bianchi et al., 2023) > =E2=80=A2 > Antioxidant and anti-hypertensive properties (Bianchi et al= ., 2023) > =E2=80=A2 > Cardiovascular protective effects (Wall et al., 2016) > =E2=80=A2 > Wound healing and collagen synthesis support in skin (Bianc= hi et al., 2023) > =E2=80=A2 > Neuroprotective effects (Bianchi et al., 2023) > =E2=80=A2 > PPAR=CE=B4 activation shown to increase MMP-9 expression, w= hich degrades IG=46-1 binding protein 3 and increases free IG=46-1 recept= or activation in endothelial progenitor cells (Han et al., 2013) > > The Cancer Question =E2=80=94 What the Science Actually Says > This is the most important section, and it requires nuance. There are c= urrently 27 published studies examining cardarine=E2=80=99s relationship = with cancer. Here=E2=80=99s how they break down (Bianchi et al., 2023): > > =E2=80=A2 > 19 studies show cardarine has pro-cancer effects (accelerat= es tumor growth) > =E2=80=A2 > 8 studies show cardarine may actually inhibit certain cance= rs and promote cancer cell death > > That 19:8 split should not be dismissed. But here=E2=80=99s the critica= l context most people miss: > The animal studies used genetically modified mice =E2=80=94 animals spe= cifically bred to be highly susceptible to cancer. These are not normal, = healthy organisms. Additionally, some studies administered cardarine for = up to 104 weeks, which represents more than half the animal=E2=80=99s ent= ire lifespan (Bianchi et al., 2023). > The dose matters enormously. In the animal models, cancer formation beg= an at doses that =E2=80=94 when converted to human equivalent doses using= validated conversion methodology =E2=80=94 are not far from what the fit= ness community commonly uses (Janhavi et al., 2022): > > =E2=80=A2 > 2mg/kg in animal models (early cancer signals) =E2=86=92 hu= man equivalent: =7E8=E2=80=9319mg/day > =E2=80=A2 > 10mg/kg in animal models (confirmed tumor growth) =E2=86=92= human equivalent: =7E40=E2=80=9397mg/day > > A 20=E2=80=9330mg/day research protocol sits uncomfortably close to tha= t lower end. > The human clinical trials tell a different story =E2=80=94 but only at = low doses. At doses of 2.5mg, 5mg, and 10mg daily for up to 12 weeks, hum= an subjects showed (Bianchi et al., 2023; Park et al., 2021): > > =E2=80=A2 > No significant adverse health effects > =E2=80=A2 > No changes in liver or muscle enzymes > =E2=80=A2 > No changes in kidney markers > =E2=80=A2 > Generally well tolerated > > The evidence suggests 10mg/day for up to 12 weeks is the dose with the = most human safety data behind it. > It is also worth noting that early research flagged a potential concern= around platelet function =E2=80=94 one animal model study found PPAR=CE=B2= /=CE=B4 agonism may inhibit platelet activation and adhesion, suggesting = a possible bleeding risk at certain doses, though this was not observed i= n the human trials (Ali et al., 2009). Additionally, one animal study fou= nd cardarine may increase sphingomyelin synthesis, raising a potential at= herosclerosis concern =E2=80=94 again not replicated in human data (Bianc= hi et al., 2023). > Practical Considerations > The dose with the most human safety data: 10mg/day, up to 12 weeks > Going beyond this increases cancer risk without a proportional benefit = payoff =E2=80=94 especially when there are other fat loss tools available= . > Cardarine + Carnitine: Why You Need Both > One of the most overlooked points: cardarine increases fatty acid beta-= oxidation, which depletes your carnitine stores (Grewal et al., 2016). Ma= ny research subjects report cardarine appears to =E2=80=9Cstop working=E2= =80=9D around weeks 4=E2=80=936. The likely reason is carnitine depletion= , not compound tolerance. > To keep fat burning running efficiently, consider pairing with: > > =E2=80=A2 > Oral L-Carnitine L-Tartrate: 1,000mg before fasted cardio += another 500=E2=80=931,000mg before training > =E2=80=A2 > Injectable L-Carnitine: 500mg before fasted cardio =E2=80=94= also has some nootropic properties in research models > > One important note: do not combine cardarine with Mildronate in researc= h protocols. They have completely opposing mechanisms. Mildronate inhibit= s carnitine synthesis while cardarine increases the demand for it. These = two compounds work against each other directly. > Detection Times > Relevant for any research subject under testing protocols (Kintz et al.= , 2021): > > =E2=80=A2 > Cardarine=E2=80=99s main metabolites (GW sulfoxide and GW s= ulphone) have extremely slow elimination rates > =E2=80=A2 > GW sulphone detectable in urine up to 40 days after a singl= e 15mg dose > =E2=80=A2 > GW sulfoxide detectable up to 25 days after a single dose > =E2=80=A2 > With repeated dosing over multiple weeks, metabolite accumu= lation extends detection significantly =E2=80=94 potentially 5+ months > =E2=80=A2 > Cardarine can also be detected in hair samples > > Estimated half-life of cardarine: approximately 16=E2=80=9324 hours bas= ed on available data (Kintz et al., 2021). > Before Running This Compound in Research > Given the cancer data =E2=80=94 even accounting for the limitations of = the animal models =E2=80=94 the responsible approach before any cardarine= research protocol includes (Bianchi et al., 2023): > > =E2=80=A2 > =46ull blood panel including cancer markers at baseline > =E2=80=A2 > Review of family history for cancer predisposition > =E2=80=A2 > Consider genetic testing for known cancer risk genes > =E2=80=A2 > Repeat blood work post-cycle > > If cancer is already present or suspected in the research subject, card= arine is off the table entirely. The in vitro human cancer cell line data= consistently shows it accelerates existing cancer cell proliferation reg= ardless of dose (Bianchi et al., 2023). > Bottom Line > The research data on cardarine is genuinely compelling =E2=80=94 the li= pid, fat loss, and endurance findings are hard to dismiss (Narkar et al.,= 2008; Wang et al., 2004; Park et al., 2021). But the cancer signal from = the animal data is equally real, and the doses commonly used in research = protocols (20=E2=80=9330mg+) exceed what has been formally studied for sa= fety in humans (Bianchi et al., 2023). > The most defensible protocol based on current evidence: 10mg/day, 12 we= eks maximum, with carnitine supplementation, and blood work before and af= ter. > The risk/reward calculation is one every researcher has to make for the= mselves =E2=80=94 but it should be made with the full picture in front of= you, not just the upside. > References > > =E2=80=A2 > Wang, Y.X. et al. (2004). Regulation of muscle fiber type a= nd running endurance by PPAR=CE=B4. PLOS Biology, 2(10):e294. > =E2=80=A2 > Narkar, V.A. et al. (2008). AMPK and PPAR=CE=B4 agonists ar= e exercise mimetics. Cell, 134(3):405-15. > =E2=80=A2 > Ali, =46.Y. et al. (2009). PPAR=CE=B2/=CE=B4 agonists modul= ate platelet function via a mechanism involving PPAR receptors and specif= ic association/repression of PKC=CE=B1. Arteriosclerosis, Thrombosis, and= Vascular Biology, 29(11):1871-3. > =E2=80=A2 > Han, J.K. et al. (2013). PPAR=CE=B4 activates endothelial p= rogenitor cells to induce angio-myogenesis through MMP-9-mediated IG=46-1= paracrine networks. European Heart Journal, 34(23):1755-65. > =E2=80=A2 > Li, S. et al. (2015). Exercise Pills: At the Starting Line.= Trends in Pharmacological Sciences, 36(12):906-917. > =E2=80=A2 > Grewal, A.S. et al. (2016). Recent Updates on PPAR=CE=B4 Ag= onists for the Treatment of Metabolic Syndrome. Journal of Medicinal Chem= istry, 12(1):3-21. > =E2=80=A2 > Wall, C.E. et al. (2016). Nuclear receptors and AMPK: can e= xercise mimetics cure diabetes=3F Journal of Molecular Endocrinology, 57(= 1):R49-58. > =E2=80=A2 > Kintz, P. et al. (2021). PPAR=CE=B4 Agonist and SARM Abuse:= Clinical, Analytical and Biological Data in a Case Involving GW1516 and = MK2866. Toxics, 9(10):251. > =E2=80=A2 > Park, J. et al. (2021). Cardarine (GW501516) Effects on Imp= roving Metabolic Syndrome. Journal of Health, Sports, and Kinesiology, 2(= 2):22-27. > =E2=80=A2 > Janhavi, P. et al. (2022). DoseCal: a virtual calculator fo= r dosage conversion between human and different animal species. Archives = of Physiology and Biochemistry, 128(2):426-430. > =E2=80=A2 > Bianchi, V.E. et al. (2023). GW501516 (Cardarine): Pharmaco= logical and Clinical Effects. Genetics & Molecular Medicine, 5(1):1-12. > > All compounds discussed are for research purposes only. Not for human c= onsumption. This post is educational and does not constitute medical advi= ce. > Upgrade to paid > You're currently a free subscriber to Peptide Price. =46or the full exp= erience, upgrade your subscription. > Upgrade to paid > > Share > > > Like > Comment > Restack > > =C2=A9 2026 Derek Pruski > 548 Market Street PMB 72296, San =46rancisco, CA 94104 > Unsubscribe --69c55348_388bd13e_733a Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline
---------- =46orwarded message ----= ------
=46rom: Derek from Peptide Price <derekpruski=40substack.com>= ;
Date: Mar 26, 2026 at 10:30=E2=80=AFAM -0400
To: tjphuhs=40gmail.com
Subject: GW501516 (Cardarine) =E2=80=94 =46ull Research Breakdown:= Mechanisms, Cancer Data, and What the Human Trials Actually Show

3D=22=22
=46or research purposes only.
=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD
=46orwarded this email=3F Subscribe here for more=

GW501516 (Cardarine) =E2=80=94 =46ull Research Breakdown: Mechanis= ms, Cancer Data, and What the Human Trials Actually Show

Derek
&=23160;=
3D=22=22
3D=22=22=
3D=22=22
3D=22=22<= /td>
READ IN APP3D=
&=23160;=

=46or research purposes only. Not fo= r human consumption.

What Is Cardarine=3F

Cardarine (also known as GW501516 or GW1516) is = a synthetic compound that activates something called the P= PAR=CE=B4 receptor (peroxisome proliferator-activated rece= ptor delta). This receptor controls genes involved in energy metabolism =E2= =80=94 specifically how your body burns fat and uses fuel.

It was originally developed to treat high cholesterol = and metabolic disorders, and early human clinical trials showed very prom= ising results. However, animal studies revealed a serious cancer concern,= and all further pharmaceutical research was abandoned. Despite this, it = remains widely used in the fitness community for fat loss and endurance.<= /p>

It is not a SARM =E2= =80=94 it has zero activity at the androgen receptor. It is on the WADA p= rohibited list, which confirms it has measurable performance effects. (Kintz et al., 2021)

3D=22=22
Upgrade to paid=

What Does Cardarine Actually Do=3F

Here=E2=80=99s a straightforward breakdown of the evid= ence-based effects:

=46at Loss & Metabolism

  • Stimulates fatty acid beta-oxidation =E2=80=94 your body burns stored fa= t for fuel more efficiently (Grewal et al., 2016)

  • Promo= tes fat loss in a caloric deficit

  • Reduces liver fat content =E2=80=94 one human trial showed a 20% reducti= on in just two weeks at 10mg/day (Park et al., 2021)

  • Reverses metabolic abnormalities in obese and pre-diabetic research subj= ects (Bianchi et al., 2023)

Blood Work / Lipid Parameters A= t 10mg/day in human clinical trials, cardarine produced measurable improv= ements (Bianchi et al., 2023; Park et al., 2021):

  • HDL (= =E2=80=9Dgood cholesterol=E2=80=9D) increased up to 16.9%

  • LDL r= educed 7=E2=80=9323%

  • Trigl= ycerides reduced 17=E2=80=9330%

  • =46as= ting insulin reduced =7E11%

  • =46re= e fatty acids reduced =7E20%

These improvements showed up in as little as two weeks= .

Endurance & Performance

  • Increases stamina and endurance capacity (Narkar et al., 2008= )

  • Shown to increase Type I (slow-twitch, endurance) muscle fibers in anima= l models (Wang et al., 2004)

  • Improves how skeletal and cardiac muscle uses energy (Li et a= l., 2015)

Other Notable Effects

  • Improves insulin sensitivity (Grewal et al., 2016)

  • Anti-inflammatory effects (systemic, brain, lungs, kidneys, liver) (Bianchi et al., 2023)

  • Antioxidant and anti-hypertensive properties (Bianchi et al.,= 2023)

  • Cardiovascular protective effects (Wall et al., 2016)

  • Wound healing and collagen synthesis support in skin (Bianchi= et al., 2023)

  • Neuroprotective effects (Bianchi et al., 2023)

  • PPAR=CE=B4 activation shown to increase MMP-9 expression, which degrades= IG=46-1 binding protein 3 and increases free IG=46-1 receptor activation= in endothelial progenitor cells (Han et al., 2013)

The Cancer Question =E2=80=94 What the Science= Actually Says

This is the most important section, and it requi= res nuance. There are currently 27 published studies examining cardarine=E2= =80=99s relationship with cancer. Here=E2=80=99s how they break down (Bianchi et al., 2023):

  • 19 studies show cardarine has pro-cancer effects (accel= erates tumor growth)

  • 8 studies show cardarine may actually inhibit certain c= ancers and promote cancer cell death

That 19:8 split should not be dismissed. But here=E2=80= =99s the critical context most people miss:

The animal studies used genetically modified m= ice =E2=80=94 animals specifically bred to be highly susce= ptible to cancer. These are not normal, healthy organisms. Additionally, = some studies administered cardarine for up to 104 weeks, which represents= more than half the animal=E2=80=99s entire lifespan (Bianchi = et al., 2023).

The dose matters enormously. In= the animal models, cancer formation began at doses that =E2=80=94 when c= onverted to human equivalent doses using validated conversion methodology= =E2=80=94 are not far from what the fitness community commonly uses (Janhavi et al., 2022):

  • 2mg/kg in animal models (early cancer signals) =E2=86=92= human equivalent: =7E8=E2=80=9319mg/day

  • 10mg/kg in animal models (confirmed tumor growth) =E2=86= =92 human equivalent: =7E40=E2=80=9397mg/day

A 20=E2=80=9330mg/day research protocol sits uncomfort= ably close to that lower end.

The human clinical trials tell a different sto= ry =E2=80=94 but only at low doses. At doses of 2.5mg, 5mg= , and 10mg daily for up to 12 weeks, human subjects showed (Bi= anchi et al., 2023; Park et al., 2021):

  • No si= gnificant adverse health effects

  • No ch= anges in liver or muscle enzymes

  • No ch= anges in kidney markers

  • Gener= ally well tolerated

The evidence suggests 10mg/day fo= r up to 12 weeks is the dose with the most human safety da= ta behind it.

It is also worth noting that early research flag= ged a potential concern around platelet function =E2=80=94 one animal mod= el study found PPAR=CE=B2/=CE=B4 agonism may inhibit platelet activation = and adhesion, suggesting a possible bleeding risk at certain doses, thoug= h this was not observed in the human trials (Ali et al., 2009)= . Additionally, one animal study found cardarine may increase = sphingomyelin synthesis, raising a potential atherosclerosis concern =E2=80= =94 again not replicated in human data (Bianchi et al., 2023).=

Practical Considerations

The dose with the most human safety data: 10mg= /day, up to 12 weeks

Going beyond this increases cancer risk without a prop= ortional benefit payoff =E2=80=94 especially when there are other fat los= s tools available.

Cardarine + Carnitine: Why You Need Both

One of the most overlooked points: cardarine inc= reases fatty acid beta-oxidation, which depletes your carnitine stores (Grewal et al., 2016). Many research subjects report = cardarine appears to =E2=80=9Cstop working=E2=80=9D around weeks 4=E2=80=93= 6. The likely reason is carnitine depletion, not compound tolerance.

To keep fat burning running efficiently, consider pair= ing with:

  • Oral L-Carnitine L-Tartrate: 1,000mg before fasted card= io + another 500=E2=80=931,000mg before training

  • Injectable L-Carnitine: 500mg before fasted cardio =E2=80= =94 also has some nootropic properties in research models

One important note: do not combine cardarine wit= h Mildronate in research protocols. They ha= ve completely opposing mechanisms. Mildronate inhibits carnitine synthesi= s while cardarine increases the demand for it. These two compounds work a= gainst each other directly.

Detection Times

Relevant for any research subject under testing = protocols (Kintz et al., 2021):

  • Carda= rine=E2=80=99s main metabolites (GW sulfoxide and GW sulphone) have extre= mely slow elimination rates

  • GW sulphone detectable in urine up to 40= days after a single 15mg dose

  • GW sulfoxide detectable up to 25 days after a single dose

  • With repeated dosing over multiple weeks, metabolite accumulation extend= s detection significantly =E2=80=94 potentially 5+ months<= /strong>

  • Cardarine can also be detected in hair samples

Estimated half-life of cardarine: approximately = 16=E2=80=9324 hours based on available data (Kintz et al., 202= 1).

Before Running This Compound in Research

Given the cancer data =E2=80=94 even accounting = for the limitations of the animal models =E2=80=94 the responsible approa= ch before any cardarine research protocol includes (Bianchi et= al., 2023):

  • =46ul= l blood panel including cancer markers at baseline

  • Revie= w of family history for cancer predisposition

  • Consi= der genetic testing for known cancer risk genes

  • Repea= t blood work post-cycle

If cancer is already present or suspected in the= research subject, cardarine is off the table entirely. The in vitro huma= n cancer cell line data consistently shows it accelerates existing cancer= cell proliferation regardless of dose (Bianchi et al., 2023).=

Bottom Line

The research data on cardarine is genuinely comp= elling =E2=80=94 the lipid, fat loss, and endurance findings are hard to = dismiss (Narkar et al., 2008; Wang et al., 2004; Park et al., = 2021). But the cancer signal from the animal data is equally r= eal, and the doses commonly used in research protocols (20=E2=80=9330mg+)= exceed what has been formally studied for safety in humans (B= ianchi et al., 2023).

The most defensible protocol based on current ev= idence: 10mg/day, 12 weeks maximum, with carnitine supplem= entation, and blood work before and after.

The risk/reward calculation is one every researcher ha= s to make for themselves =E2=80=94 but it should be made with the full pi= cture in front of you, not just the upside.

References

  • Wang, Y.X. et al. (2004). Regulation of muscle fiber type and running en= durance by PPAR=CE=B4. PLOS Biology, 2(10):e294.

  • Narkar, V.A. et al. (2008). AMPK and PPAR=CE=B4 agonists are exercise mi= metics. Cell, 134(3):405-15.

  • Ali, =46.Y. et al. (2009). PPAR=CE=B2/=CE=B4 agonists modulate platelet = function via a mechanism involving PPAR receptors and specific associatio= n/repression of PKC=CE=B1. Arteriosclerosis, Thrombosis, and V= ascular Biology, 29(11):1871-3.

  • Han, J.K. et al. (2013). PPAR=CE=B4 activates endothelial progenitor cel= ls to induce angio-myogenesis through MMP-9-mediated IG=46-1 paracrine ne= tworks. European Heart Journal, 34(23):1755-65.

  • Li, S. et al. (2015). Exercise Pills: At the Starting Line. T= rends in Pharmacological Sciences, 36(12):906-917.

  • Grewal, A.S. et al. (2016). Recent Updates on PPAR=CE=B4 Agonists for th= e Treatment of Metabolic Syndrome. Journal of Medicinal Chemis= try, 12(1):3-21.

  • Wall, C.E. et al. (2016). Nuclear receptors and AMPK: can exercise mimet= ics cure diabetes=3F Journal of Molecular Endocrinology, 57(1):R49-58.

  • Kintz, P. et al. (2021). PPAR=CE=B4 Agonist and SARM Abuse: Clinical, An= alytical and Biological Data in a Case Involving GW1516 and MK2866. Toxics, 9(10):251.

  • Park, J. et al. (2021). Cardarine (GW501516) Effects on Improving Metabo= lic Syndrome. Journal of Health, Sports, and Kinesiology<= span>, 2(2):22-27.

  • Janhavi, P. et al. (2022). DoseCal: a virtual calculator for dosage conv= ersion between human and different animal species. Archives of= Physiology and Biochemistry, 128(2):426-430.

  • Bianchi, V.E. et al. (2023). GW501516 (Cardarine): Pharmacological and C= linical Effects. Genetics & Molecular Medicine,= 5(1):1-12.

All compounds discussed are for research purposes = only. Not for human consumption. This post is educational and does not co= nstitute medical advice.

Upgrade to paid=

You're= currently a free subscriber to Peptide Price. =46or the full experience, upgrade your subscription.

Upgrad= e to paid

&=23160;=
3D=22=22Share
&=23160;=
&=23160;=
3D=22=22Like
3D=Comment
3D=22=22Restack
&=23160;=

=C2=A9 2026 Derek Pruski
548 Market Street PMB 72296, San =46rancisco, CA 94104
Unsubscribe

3D=22Start
3D=22=223D=22=22
--69c55348_388bd13e_733a--